Insurance For Experimental Technology Companies UK: 2026 Guide
Why does experimental technology need specialist insurance — not standard commercial cover?
Standard commercial insurance was written for a world of known products, established processes, and predictable failure modes. Experimental technology companies operate in precisely the opposite environment — building products that have never existed, deploying processes that have no industry precedent, and commercialising technologies whose failure modes regulators haven't yet codified. The standard commercial policy response to unknown risk is exclusion: "untested products," "experimental processes," "new technology" — the clauses that protect mainstream insurers are exactly the clauses that leave experimental tech companies uninsured at the moment they most need cover.
The UK experimental technology sector is also facing a regulatory transformation that has fundamentally changed the liability picture. The Product Regulation and Metrology Act 2025 received Royal Assent on 21 July 2025, giving the UK Government sweeping powers to regulate digital products, AI systems, software components, and emerging technologies for the first time as a unified domestic framework. Simultaneously, the Law Commission launched a full-scale review of UK product liability under the Consumer Protection Act 1987 — the first such review since 1987 — to address how liability applies to software defects, embedded AI decision-making, and cybersecurity vulnerabilities. Experimental tech companies are building into a regulatory regime that is mid-reformation. What the law will look like when their products reach market is genuinely uncertain — and standard insurers price that uncertainty by excluding it.
The practical consequence: a robotics startup using a generic contractor's PI policy; an AI software developer relying on a standard tech E&O policy with a broad AI exclusion; a medical device innovator relying on a commercial combined policy that excludes "novel or untested products" — these companies may hold certificates of insurance that provide almost no actual cover for the claims they are most likely to face. This guide maps the genuine risk exposures for experimental technology businesses in 2026, explains the cover architecture that responds, and identifies the specific placement decisions that make the difference between a paper insurance programme and a functional one. It complements our AI and tech insurance hub and our specialist guides on robotics startup insurance, prototype development insurance, and AI consultancy insurance.
Key facts at a glance
- The Product Regulation and Metrology Act 2025 (PRAM Act) received Royal Assent on 21 July 2025 — for the first time, UK product safety law explicitly covers "intangible components" including software and AI algorithms. Secondary legislation will impose specific obligations; experimental tech companies should be preparing documentation compliance now.
- The Law Commission's product liability review (launched July 2025) is the first since 1987 — it is expected to clarify how UK law applies to software defects, AI decision-making errors, and cybersecurity vulnerabilities. The outcome will materially change product liability exposure for tech companies through 2026–2027 and beyond.
- Standard commercial policies routinely carry "novel technology," "untested products," and "AI" exclusions — these exclusions may void cover for the categories of product that most experimental tech companies actually build. Explicit confirmation that cover applies to your technology type is essential before relying on any policy.
- Intellectual property disputes are rising sharply — IP insurance submissions were up 40% in H1 2025 according to Tokio Marine Kiln, driven by AI and software firms and rising litigation risk around technology licensing. Average UK IP claim values exceed £150,000.
- Investor due diligence now routinely includes insurance review — VCs and angel investors at Series A and beyond increasingly require evidence of PI, product liability, D&O, and cyber cover before completing investment rounds. Inadequate insurance can delay or block funding.
- AI-specific exclusions in standard policies are expanding — several mainstream insurers updated policy wordings in 2025 to include explicit AI carve-outs following regulatory pressure. Tech companies relying on pre-2025 policies should urgently check renewal terms for new exclusion language.
- UK experimental technology insurance typically costs £2,500–£25,000+ annually depending on technology type, development stage, revenue, and documentation maturity — with product liability and PI as the dominant cost drivers for higher-risk categories including medical devices, autonomous systems, and AI decision-making tools.
1. The 8 biggest risks for experimental tech companies: summary table
Experimental technology companies face a risk profile that is simultaneously broader and less predictable than any other commercial sector. The table below ranks the primary exposures by combined frequency, severity, and 2026 regulatory impact. Several — product liability, IP disputes — are existential. Others — environmental liability, non-disclosure — are less visible but equally capable of leaving a company without cover at the critical moment.
| Risk | Frequency | Severity | Primary Cover |
|---|---|---|---|
| Product liability — untested technology | Rising sharply with PRAM Act | Catastrophic (no cap) | Products Liability; Tech PI |
| Professional indemnity — advice and technology failure | Common across delivery stages | High (£50k–£2m+) | Professional Indemnity (Tech PI) |
| Intellectual property disputes | Rising — 40% increase in H1 2025 | High (£150k+ average UK claim) | IP Liability; Legal Expenses |
| Cyber liability and AI failure | Frequent — breach rates rising | High (£50k–£5m+) | Cyber Insurance; Tech E&O |
| Prototype damage, loss, and testing failure | Routine in R&D stage | Medium (£10k–£500k+) | All Risks (Prototype); PL |
| Directors & Officers liability — investor disputes | Rising with VC deal activity | High (£100k–£2m+) | D&O Insurance |
| Environmental and regulatory liability | Occasional — sector-dependent | Medium-High (£25k–£500k) | EIL; Public Liability |
| Insurance non-disclosure / AI exclusion gaps | Very common — often undetected | Catastrophic (total uninsured loss) | Specialist placement only |
2. How does the Product Regulation and Metrology Act 2025 change liability for tech innovators?
The Product Regulation and Metrology Act 2025 (PRAM Act) is the most significant shift in UK product safety and liability law in nearly four decades. For experimental technology companies, its implications are practical and immediate — even though the Act is framework legislation that creates powers rather than immediate compliance obligations.
What the PRAM Act does for the first time
The PRAM Act is the first piece of UK legislation to explicitly bring "intangible components" — including software, algorithms, and AI systems — within the scope of product safety regulation. Previously, the Consumer Protection Act 1987 governed product liability for physical goods, but its application to software products, embedded AI, and digital components was legally uncertain and practically untested. The PRAM Act creates a framework under which the Secretary of State can now introduce specific regulations for any product — physical or digital — for the purpose of reducing risks, ensuring efficacy, and setting standards. For experimental tech, this means:
- Secondary legislation through 2026–2028 will progressively impose safety documentation, risk assessment, and reporting obligations on digital product manufacturers including software developers and AI system builders.
- The lifecycle approach of the PRAM Act means regulatory obligations may extend beyond the point of sale to cover software updates, integrations, and changes throughout a product's operational life — meaning ongoing compliance obligations for subscription or SaaS-model tech businesses.
- UK and EU requirements may diverge: companies trading in both markets will need parallel safety documentation for UK (PRAM Act) and EU (Product Liability Directive 2024/2853) regimes.
- The Law Commission's concurrent product liability review is expected to clarify — and likely expand — the circumstances in which companies can be held liable for software defects, AI decisions, and cybersecurity failures.
What this means for insurance now
The PRAM Act creates an immediate insurance relevance in three ways. First, it signals the direction of UK product liability law — and insurers are already pricing that signal into how they assess experimental technology risks. Second, it creates a documentation and compliance environment that specialist insurers require as a condition of cover: tech companies with robust safety documentation attract better terms. Third, it means that "untested product" exclusions in standard commercial policies — already problematic for experimental tech — will become progressively more litigated as the secondary legislation crystallises what "tested" and "safe" means for digital products.
3. Risk 1: Product liability for untested technology — the existential exposure
Product Liability — Untested Technology Claims
Product liability for experimental technology is categorically different from standard product liability. In standard product liability, the failure mode is known — a manufactured item fails in a predictable way and causes injury or property damage. In experimental technology, the failure modes may be entirely novel: an AI system makes a consequential decision that no human would have taken; a prototype device interacts with an environment in an unforeseen way; a software component cascades through a system creating damage that no safety test anticipated. The Consumer Protection Act 1987 imposes strict liability on producers — meaning a claimant does not need to prove negligence, only that the product was defective and caused the loss. For novel technology where the standard of "not defective" has never been defined by regulation, this is an extremely uncertain liability position.
Rigorous pre-commercialisation safety testing with documented test protocols; PRAM Act compliance-ready technical documentation for any digital or AI-embedded product; clear product scope limitations in client-facing documentation (what the product does and explicitly does not do); phased commercialisation with controlled beta/pilot environments where liability can be contractually managed; insurance for the testing and development phase as well as the commercial phase; legal review of any warranties, guarantees, or fitness-for-purpose representations in sales materials.
Products Liability with explicit experimental/novel technology scope — not a standard commercial products endorsement. Specialist tech insurers and Lloyd's market syndicates underwrite this risk; mainstream commercial markets routinely exclude it. Cover typically £1m–£10m limits depending on product category. Medical device, autonomous vehicle, and AI decision-making system products require specialist placement with Lloyd's market underwriters. Claims have no statutory cap under CPA 1987; catastrophic injury or multiple-claimant scenarios have unlimited theoretical liability. Standard "products completed operations" endorsements on commercial combined policies are almost never adequate for experimental technology.
4. Risk 2: Professional indemnity — errors, advice, and technology failure
Professional Indemnity — Technology E&O and Advice Liability
Professional indemnity for experimental technology businesses covers the gap between product liability (what the product does) and professional liability (what the company advised, designed, specified, or delivered as a professional service). For experimental tech companies, the PI exposure is particularly acute because: the company typically occupies both the product manufacturer and the professional advisor role simultaneously; clients rely heavily on the company's technical expertise for decision-making because no independent standard exists; and early-stage companies often make verbal commitments about performance, timescales, and capabilities that can be construed as professional representations if the technology falls short.
Technology-specific PI (often called Tech E&O — Errors and Omissions) covers claims arising from: failure of software to perform as specified; negligent technology design or architecture advice; failure to meet agreed technical milestones or performance standards; technology integration errors causing downstream system damage; and inadequate security design leading to data breach. The specific challenge for experimental tech is that the standard of care — what a "reasonable" professional in this technology type would have done — may not yet exist in case law or professional guidance. That ambiguity cuts both ways: it makes claims harder to prove but also harder to defend without expert technical evidence.
Detailed written specifications for all client engagements with explicit performance metrics, exclusions, and limitations of liability clauses; documented technical decision logs for significant design choices; client-facing milestone and acceptance testing criteria agreed in writing before delivery; clear IP ownership provisions in all client contracts; documented handling of client-reported defects and the resolution process; professional indemnity-aware review of any marketing claims that might be construed as performance warranties.
Technology Professional Indemnity (Tech PI / Tech E&O) with explicit scope for software failure, AI/algorithmic errors, systems integration, and advisory liability. Standard professional indemnity policies for accountants, consultants, or architects are not appropriate — they exclude technology-specific failure categories. Tech PI should cover: negligent design, specification errors, delivery failure, privacy liability, and IP infringement arising from professional services. Limits typically £250k–£2m for SMEs; £2m–£10m for companies with enterprise client contracts or regulated sectors. Run-off cover is essential — PI claims are brought on a "claims made" basis and can surface years after the original engagement. See our professional indemnity insurance guide for cover principles applicable across tech PI products.
5. Risk 3: Intellectual property disputes and infringement claims
Intellectual Property Disputes — The Fastest-Growing Tech Risk
Intellectual property disputes are the fastest-growing insurance risk category for experimental technology companies in 2026. IP insurance submissions were up 40% in H1 2025, driven primarily by AI and software firms facing rising litigation around technology licensing and patent infringement. The average UK IP claim now exceeds £150,000 — a figure that will absorb most of the operating cash of an early-stage tech company. The specific drivers for experimental tech are: AI training data copyright disputes (where generative AI systems may have been trained on copyrighted material); patent infringement claims from patent assertion entities (PAEs) who hold broad technology patents and target commercialising startups; trade secret misappropriation claims where former employees or collaborators allege proprietary information was used in new developments; and disputes over ownership of IP developed collaboratively with university research partners or contractors.
The "freedom to operate" question — whether a new technology can be commercialised without infringing existing patents — is a critical pre-commercialisation legal step that many UK startups under-resource. The consequence: they discover infringement risk only when a claim is filed, at which point the cost of defence alone can be £200,000–£500,000 before any settlement.
Freedom to operate (FTO) search before commercialisation of any novel technology; patent filing strategy for core innovations with IP solicitor advice; clear IP assignment clauses in all employment, contractor, and collaboration agreements; documented data provenance for any AI system trained on external datasets; IP ownership audit before any funding round or acquisition; non-disclosure agreements with all external collaborators; documented university spinout IP arrangements reviewed by specialist IP solicitors.
IP Liability Insurance covering defence costs and damages for claims that your technology infringes third-party IP rights. Legal Expenses Insurance with IP infringement scope covering the cost of pursuing infringers of your own IP. These are separate covers — IP liability is a defence policy; IP prosecution is an offensive policy. Both are available from specialist insurers and via Lloyd's market placement. The combination typically costs £2,000–£8,000 annually for an early-stage tech company — substantially less than a single claim defence cost. Standard commercial policies and generic Tech PI policies typically do not include IP liability; it requires specific placement or explicit endorsement.
6. Risk 4: Cyber liability, data breach, and AI failure
Cyber Liability and AI Failure — The Converging Risk
Experimental technology companies face cyber risk at two levels simultaneously: as technology businesses holding client and employee data (universal cyber exposure), and as builders of connected, networked, or data-dependent technologies whose compromise creates downstream liability for their clients' losses (technology-specific cyber exposure). AI systems add a third dimension: the failure or manipulation of an AI model — through adversarial attacks, model poisoning, or prompt injection — can cause consequential decisions by the AI system that are indistinguishable from a cybersecurity breach in terms of financial impact but may not be covered by standard cyber policies that focus on data exfiltration and ransomware.
The regulatory landscape under the UK GDPR and Data Protection Act 2018 imposes fines of up to £17.5m or 4% of global annual turnover for serious data protection breaches. The ICO's enforcement posture has hardened since 2024 — experimental tech companies processing novel categories of personal data (biometric data, behavioural data, AI-generated profiles) face heightened regulatory scrutiny. ICO enforcement action, even where no fine is ultimately imposed, can cost £50,000–£150,000 in legal and advisory costs to manage.
Data Protection Impact Assessments (DPIAs) for any technology processing sensitive personal data; penetration testing of all client-facing systems annually; documented incident response plan with defined escalation paths; supply chain security assessment for any third-party APIs, datasets, or AI model dependencies; ICO registration and Article 30 record of processing activities; AI-specific security documentation (model governance, adversarial testing, access controls) where AI systems process personal data or make automated decisions; NIS2-equivalent critical information infrastructure obligations where technology is deployed in regulated sectors.
Cyber Insurance with both first-party (own business costs) and third-party (client and regulatory liability) scope. For experimental tech companies, the third-party liability element is particularly important — if a client's system is compromised through a failure in your technology, their losses are your third-party cyber exposure. Tech E&O and Cyber are often bundled in specialist tech policies; check that both elements are adequately scoped. AI failure cover — where the model produces an erroneous output causing client financial loss — is an emerging coverage category that should be explicitly confirmed or declined in writing. See our cyber insurance guide for the full cover architecture that applies to tech businesses.
7. Experimental tech insurance cover checker
Select your company profile below to see the insurance programme matched to your specific risk exposure. For Miller & Partner's specialist tech and AI insurance product page see our AI and tech insurance hub.
Experimental Tech Insurance Cover Checker
Select your company profile to see the cover matched to your specific risk — including the gaps that standard policies routinely miss
AI / Machine Learning Company
- CRITICAL Verify that your Tech PI policy explicitly covers AI-generated outputs and algorithmic failure — standard Tech PI often excludes this
- ESSENTIAL Technology Professional Indemnity £1m–£5m with AI and machine learning scope explicitly confirmed in writing
- ESSENTIAL Cyber Insurance with AI failure and third-party technology liability scope — not just data breach cover
- ESSENTIAL IP Liability Insurance — AI training data copyright disputes are a major and rising exposure
- ESSENTIAL Products Liability where AI system makes autonomous decisions affecting physical systems or persons
- ESSENTIAL Directors & Officers (D&O) — investor and regulatory exposure rising with AI governance requirements
- LEGAL Employers' Liability £10m where staff employed
- RECOMMENDED Legal Expenses with ICO investigation, IP litigation, and contract dispute scope
- RECOMMENDED Run-off PI cover — AI liability claims can surface years after system deployment
Robotics / Autonomous Systems Company
- CRITICAL Products Liability for autonomous systems requires Lloyd's market specialist placement — standard commercial markets exclude this category
- LEGAL Employers' Liability £10m where staff employed
- ESSENTIAL Products Liability £5m–£10m+ with autonomous and semi-autonomous system scope confirmed in policy wording
- ESSENTIAL Technology PI £1m–£5m covering design and specification errors, integration failure, and navigation/autonomy advisory liability
- ESSENTIAL Prototype and development equipment All Risks — field testing and demonstrator units
- ESSENTIAL Public Liability £5m–£10m for testing, demonstration, and deployment scenarios involving third parties
- ESSENTIAL Cyber Insurance — connected autonomous systems face cyber-physical attack risk
- ESSENTIAL D&O — funding round and regulatory exposure
- RECOMMENDED IP Liability — robotics and autonomous systems innovation is heavily patent-contested territory
MedTech / Health Tech Innovator
- CRITICAL MedTech product liability is the highest-stakes experimental tech category — specialist Lloyd's placement is non-negotiable
- LEGAL Employers' Liability £10m comprehensive
- ESSENTIAL Products Liability £5m–£10m+ with medical device and health technology scope — MHRA regulatory compliance documentation required
- ESSENTIAL Technology PI £2m–£5m covering clinical decision support errors, diagnostic failure, and health data liability
- ESSENTIAL Cyber Insurance with health data scope — patient data breach carries ICO and CQC exposure simultaneously
- ESSENTIAL Clinical trial and product recall cover where devices are in any stage of human use
- ESSENTIAL D&O — MHRA regulatory action and investor liability exposure
- ESSENTIAL Legal Expenses with MHRA, ICO, and CQC regulatory investigation scope
- RECOMMENDED IP Liability — medical device patent landscape is heavily contested
Hardware / Prototype Developer
- LEGAL Employers' Liability £10m where staff employed
- ESSENTIAL All Risks (Prototype) insurance covering prototypes and development units during build, test, transport, and field demonstration
- ESSENTIAL Products Liability with novel/experimental product scope — confirm the "untested product" exclusion has been removed or scoped out
- ESSENTIAL Public Liability £2m–£5m for testing and demonstration scenarios
- ESSENTIAL Technology PI where hardware design is sold as a professional service
- ESSENTIAL Tools and equipment — specialist manufacturing equipment and test rigs
- RECOMMENDED IP Liability — hardware innovations attract patent assertion entity activity
- RECOMMENDED D&O for funded companies
- CONSIDER Product Recall Expenses where hardware has entered any commercial deployment stage
Deep Tech / University Spinout
- CRITICAL University IP arrangements require explicit legal and insurance review — don't assume university indemnities extend to the spinout entity
- LEGAL Employers' Liability £10m where staff employed
- ESSENTIAL Technology PI £1m–£5m with research and experimental process scope
- ESSENTIAL Products Liability for any technology being commercialised — even in early pilot stage
- ESSENTIAL IP Liability — university spinouts face particular exposure from licensing disputes, background IP boundaries, and competitive academic research fields
- ESSENTIAL D&O — investor liability and University Technology Transfer Office disputes
- ESSENTIAL Research equipment All Risks — specialist and often irreplaceable equipment
- RECOMMENDED Cyber Insurance with research data scope
- RECOMMENDED Legal Expenses with IP litigation and contract dispute scope
SaaS / Software with AI Components
- CRITICAL AI components in SaaS create a product liability exposure that standard SaaS Tech PI may not cover — get explicit written confirmation
- LEGAL Employers' Liability £10m where staff employed
- ESSENTIAL Technology PI £500k–£2m with AI and automated decision-making scope confirmed — not generic software PI
- ESSENTIAL Cyber Insurance comprehensive — first and third-party, including AI failure scope
- ESSENTIAL Products Liability where AI component makes autonomous decisions affecting clients or end-users
- ESSENTIAL IP Liability — AI training data and software IP disputes are increasingly common
- RECOMMENDED D&O for funded companies
- RECOMMENDED Legal Expenses with contract dispute and regulatory investigation scope
- CONSIDER Media Liability where AI-generated content forms part of the product output
8. Insurance red flag self-check — are you exposing your company?
The most dangerous insurance gaps for experimental technology companies are rarely noticed until a claim is filed. Click each statement that applies to your business. Each flag represents a potential uninsured exposure in your current cover.
Experimental Tech Insurance Red Flag Checker
Click any statement that is true for your business. Each flagged item represents a potential gap in your current cover that needs specific attention.
-
Our Tech PI policy has not been specifically checked for AI exclusions since 2024 — several mainstream insurers added AI carve-outs at 2025 renewals
-
We have no IP Liability insurance — our technology involves novel patents, AI training data, or licensed third-party components
-
We have not confirmed in writing that our products liability policy covers our specific technology type — our broker described us as a "tech company" generically at proposal
-
We process personal data using AI or automated decision-making but have not conducted a DPIA and do not have cyber cover with AI failure scope
-
We are a funded company with VC investors but have no D&O insurance — investor-related director disputes are uninsured
-
We have not done a freedom-to-operate search on our core technology — patent infringement risk has not been assessed
-
Our prototype or development equipment is not specifically insured — we rely on a commercial contents policy that excludes experimental or prototype items
-
Our technology has entered a pilot or beta deployment but we still hold development-stage insurance without reviewing whether product liability now applies
-
We have IP developed with university partners or contractors but have not confirmed in writing who owns it — IP ownership disputes are uninsured until they crystallise as a claim
-
We have not reviewed our insurance programme against the PRAM Act 2025 — our product documentation and safety testing records may not meet the framework's emerging standards
9. Experimental technology company risk assessor
Two factors drive insurance risk and premium cost above all others for experimental tech companies: the type of technology being developed, and how far it has progressed toward deployment with real-world users. Use the tool below to profile your specific risk position.
Experimental Tech Operation Risk Assessor
Select your technology type and deployment stage to see your specific risk profile and the insurance programme that applies
10. Risk 5: Prototype damage, loss, and testing failure
Prototype and Development Asset Risk — Often the Largest Uninsured Asset
For hardware-based experimental technology companies, prototypes and development units represent a disproportionate concentration of value — often the single most expensive asset the company holds, frequently irreplaceable in the short term, and almost always inadequately insured. Standard commercial contents policies exclude "experimental," "prototype," and "one-off" items — exactly the categories that experimental tech companies hold. Field testing introduces additional risks: environmental damage, transportation damage, third-party property damage during testing scenarios, and testing failure claims where a client or partner suffers loss as a direct result of the prototype's malfunction during a demonstration or pilot deployment.
Documented prototype asset register with replacement cost valuation for each unit; controlled testing environment protocols specifying who can be present during testing; written testing agreements with third-party host sites setting out liability allocation; transportation protocols for high-value or fragile prototype units; environmental condition monitoring during field tests; documented handover process when prototypes leave company premises; photographic condition records before and after any field deployment.
Specialist All Risks cover for prototypes and development units — not standard commercial contents or property cover. This requires either a standalone specialist prototype policy or explicit endorsement to a commercial combined policy that removes the "prototype/experimental" exclusion. Cover should extend to: laboratory environments, field testing, transportation, client site demonstrations, and storage at third-party facilities. Public Liability for testing scenarios should explicitly cover prototype malfunction and testing failure claims. Our specialist guide on prototype development insurance covers this in detail for hardware-focused innovators.
11. Risk 6: Directors and officers liability — investors, disputes, and regulatory action
Directors and Officers Liability — The Risk Investors Create
Directors and Officers (D&O) insurance is disproportionately underpenetrated in the experimental technology sector — particularly among early-stage companies that assume it is a "large company" product. The reality is that D&O exposure rises sharply at the point of any external investment. Once investors hold equity, directors have fiduciary duties to those investors that can be the subject of claims. Technology direction decisions, fundraising representations, burn rate management, IP strategy decisions, and regulatory compliance failures can all generate D&O claims when a company fails to meet investor expectations or a technology pivot destroys invested value.
The regulatory dimension is also rising. As the PRAM Act secondary legislation develops, company directors may face personal liability for product safety failures where they were involved in decisions about commercialising technology that later proved unsafe. The Companies Act 2006 and Insolvency Act 1986 both create personal director liability routes in corporate failure scenarios — particularly relevant for high-burn experimental tech companies operating close to their funding runway.
Board-level documentation of key technology direction decisions and the information on which they were based; investment round representations reviewed by solicitors before any investor communication; clear board minutes for all major strategic decisions; documented management information given to investors (monthly board packs); employment practices liability documentation for any employee-related decisions; proactive regulatory engagement strategy where MHRA, ICO, or FCA oversight is anticipated; corporate governance framework appropriate to funding stage.
Directors and Officers Insurance covering the personal legal liability of directors and officers for wrongful acts in their management of the company. D&O should include: company entity cover; employment practices liability; outside director cover where directors sit on partner or investee boards; Run-off cover on M&A or IPO events (the most common trigger for pre-IPO D&O claims surfacing). Most VCs at Series A and beyond will require evidence of D&O cover as a condition of the investment agreement. Limits typically £1m–£5m for funded early-stage companies; £5m–£10m+ for Series B and beyond. Claims have surfaced for funded UK tech startups at £200,000–£800,000 for contested investment round disputes.
12. Risk 7: Environmental and regulatory liability in experimental processes
Environmental and Regulatory Liability — Experimental Processes and Novel Materials
Deep technology companies working with novel materials, biological agents, chemical processes, or advanced manufacturing techniques face environmental liability exposure that standard commercial policies routinely exclude. Experimental processes by definition haven't been through the regulatory risk assessment that established processes have — meaning environmental release events, disposal failures, and laboratory incidents can create liability with no precedent for either the company or their insurer to reference. REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) obligations apply to novel chemical compounds; biotech companies face MHRA and HSE GM containment regulatory obligations; battery and energy storage innovators face Environment Agency obligations for novel chemistries.
Environmental risk assessment for any process involving novel materials, chemical compounds, or biological agents; documented waste disposal protocols with licensed carriers for any experimental process waste; HSE consultation on containment classifications for biological or chemical innovation; REACH obligations review for novel chemical compounds before any manufacturing or sale; documented laboratory safety protocols reviewed against HSE COSHH obligations; Environment Agency registration where required for experimental processes generating controlled waste.
Environmental Impairment Liability (EIL) for experimental processes involving chemical, biological, or novel material hazards. Standard Public Liability policies carry broad pollution exclusions — EIL fills the gap. For experimental tech companies handling controlled substances or operating under regulatory permit conditions, EIL should be specific to the process and material categories involved. Specialist Lloyd's market underwriters are the primary route for deep tech environmental liability cover. Legal Expenses with HSE investigation and Environment Agency enforcement scope provides defence cost cover for the regulatory dimension.
13. Risk 8: Insurance non-disclosure and the AI exclusion problem
Non-Disclosure and Exclusion Gaps — The Most Preventable Catastrophe
The most common reason experimental technology insurance claims fail is not because the event was unforeseeable — it's because the policy was never correctly described or placed in the first place. The Insurance Act 2015 requires businesses to make a "fair presentation of the risk" at proposal, proactively disclosing every material fact an insurer would want to know. For experimental technology companies, the specific failure modes are: describing a company as a "software business" or "tech consultancy" when it is actually an AI product company with autonomous decision outputs; failing to disclose AI components in what is presented as a standard SaaS product; presenting as a "hardware prototype developer" without specifying the regulatory environment (MedTech, autonomous vehicles) in which the hardware operates; and failing to flag that the technology has progressed from development stage to commercial deployment between renewals.
The AI exclusion problem compounds this. As noted above, several mainstream insurers updated policy wordings in 2025 to include explicit AI carve-outs. A company that held an adequate Tech PI policy in 2024 may have an inadequate one at the 2025 renewal — with the new exclusion language buried in updated policy wording that neither the client nor their generic broker specifically reviewed against the company's technology profile.
Annual review of declared activities against actual technology operations at every renewal; written confirmation from broker that all technology categories — AI, autonomous systems, novel hardware, medical applications — are within declared scope; specific flagging of any technology progression from development to commercial deployment as a mid-term notification; annual review of policy wording for new exclusion language against company's technology profile; written broker confirmation that no AI exclusion has been added or modified at renewal; retention of all proposal documentation and broker correspondence as evidence of disclosure.
There is no insurance response to non-disclosure — that is precisely the point. The only protection is at the proposal and renewal stage: specific and technically accurate description of the technology, its deployment stage, its application sectors, and its regulatory environment. Specialist experimental tech brokers who understand the difference between a "software company" and an "AI decision-making platform" make a material difference at proposal. A generic broker placing an experimental tech company into a standard tech PI product may genuinely not ask the questions that surface the disclosures that would change the underwriting outcome. That's not fraud — it's structural inadequacy in how the risk is placed.
14. What drives the cost of experimental technology insurance in 2026?
Experimental technology insurance pricing in 2026 reflects the genuine difficulty of underwriting innovation: unknown failure modes, evolving regulation, and the absence of actuarial claims history for many technology categories. Indicative annual premium ranges:
| Company Profile | Indicative Annual Premium 2026 |
|---|---|
| Software / SaaS without AI components — R&D to early commercial, <£500k revenue | £2,500–£6,000 |
| AI / ML startup — pilot to early commercial, AI decision output, £100k–£1m revenue | £6,000–£15,000 |
| Hardware prototype developer — R&D to early commercial, £100k–£500k revenue | £5,000–£12,000 |
| Robotics / autonomous systems company — pilot to commercial, £250k–£2m revenue | £12,000–£30,000 |
| MedTech innovator — any commercial stage with MHRA engagement, £500k–£5m revenue | £15,000–£45,000+ |
| Deep tech / university spinout — funded growth, complex IP, £1m–£5m revenue | £10,000–£35,000 |
| Scaled AI / tech platform — Series B+, enterprise clients, £5m+ revenue | £25,000–£80,000+ |
The rating factors below drive both premium level and programme structure for experimental technology companies. Documentation maturity — specifically the technical evidence that supports PRAM Act compliance, DPIA completion, and IP provenance — is the single biggest within-category premium lever available to well-managed companies.
| Rating Factor | Impact on Premium | What You Can Do |
|---|---|---|
| Technology type and autonomy level | Software lowest; autonomous systems and MedTech highest — often 3–5× premium differential | Accurate technical description at proposal; don't understate autonomy level |
| Deployment stage and user base | Internal R&D lowest; scaled commercial with enterprise clients highest | Mid-term notification when stage changes — don't wait for renewal |
| Revenue and client contract values | Primary PI and PL scaling factors | Declare accurately including planned growth under funded expansion |
| PRAM Act compliance documentation | Mature PRAM-ready tech documentation reduces PL premium 10–20% | Safety testing records, product scope documents, technical file per product |
| AI and algorithmic documentation | Model governance, adversarial testing records, AI-specific DPIA reduce cyber/PI premium 8–15% | Implement model documentation discipline; evidence at every renewal |
| IP documentation maturity | Completed FTO searches and patent filing strategy reduce IP liability premium 5–15% | Commission FTO before commercialisation; file patents for core innovations |
| Claims history | Single PI or PL claim has 3–5 year premium impact; IP claims particularly material | Root cause documentation and remediation evidence after any claim |
| Sector regulatory environment | Unregulated sectors lowest; MHRA (MedTech), FCA (FinTech), CAA (autonomous aviation) highest | Early regulatory engagement and documented compliance strategy reduces insurer risk perception |
| Client contract risk allocation | Uncapped liability to clients dramatically increases PI limits required and premium | Negotiate liability caps and indemnity limitations in client contracts |
| Cyber security posture | Penetration testing, ISO 27001 alignment, MFA deployment reduce cyber premium 10–20% | Annual pen testing; evidence at renewal |
| Broker and market placement | Specialist tech brokers with Lloyd's access vs generic commercial brokers — material premium and coverage quality difference | Use a broker with demonstrable experimental tech underwriting experience |
| D&O investor requirements | VC due diligence requirements drive D&O limits — typically £1m–£5m at Series A | Arrange D&O before investor due diligence begins; not as an afterthought |
15. Real claims and how experimental tech companies should manage them
Claim — AI Decision-Making PI, £280,000 Settlement
A UK AI startup had developed a credit decisioning model sold as a SaaS product to a mid-sized fintech lender. The model incorporated machine learning trained on historical lending data to produce automated credit scores. The lender used the model as the primary input to credit decisions for 14 months. An internal audit by the lender identified that the model had systematically underscored a demographic segment of applicants — an output the lender's legal team characterised as indirect discrimination under the Equality Act 2010. The lender faced regulatory scrutiny from the FCA and brought a PI claim against the AI startup for negligent model design and failure to disclose the training data demographic characteristics at proposal.
The AI startup's Tech PI policy responded — but only after a five-month coverage dispute. The policy had been placed as a generic "software company" PI without specifically declaring that the product made autonomous credit decisions. The insurer's initial position was that the policy was placed for advisory services, not automated decision-making that constituted regulated financial activity. The dispute was resolved by reference to the proposal documentation, which was interpreted broadly enough to include the product. Settlement: £280,000 (regulatory remediation costs, affected customer redress fund contribution, legal costs). Defence costs: £45,000. Total claim: £325,000.
Post-claim renewal: PI premium increased 55%. Insurer required: explicit model governance documentation; demographic bias testing records for all model versions; DPIA completed for the credit model; specific disclosure of automated decision-making in the proposal. The startup implemented these and the following renewal saw premium return to a 28% loading over pre-claim baseline.
The lesson: AI decision-making products are not "software" for insurance proposal purposes — they are a specific and higher-risk category that requires explicit declaration. A startup that describes its AI credit model as a "software product" at proposal has likely made a material non-disclosure under the Insurance Act 2015. Specialist brokers know to ask; generic ones often don't.
Claim — Prototype Field Testing PL, £148,000 Settlement
A robotics company was demonstrating an autonomous material-handling prototype at a prospective client's warehouse facility. The demonstration was a contractually agreed pilot session with two company engineers present and three of the client's operations staff observing. During the demonstration, the prototype's navigation system lost positional reference in a section of the warehouse where GPS signal was attenuated by the metal racking structure. The unit collided with a racking column, causing a partial racking collapse. Two of the client's staff suffered minor injuries requiring hospital attendance; one sustained a soft tissue injury that later developed into a six-month absence from work.
The robotics company's Public Liability policy responded — but the initial claim also included a product liability element that the insurer disputed. The PL policy covered third-party injury and property damage during the demonstration; the product liability element (the argument that the navigation failure was a product defect) was initially contested on the basis that this was a "prototype unit not yet in commercial production." Resolution: the PL insurer accepted the claim on both injury and property elements; the PL/PL boundary dispute was resolved by treating the demonstration as an operational activity rather than product deployment. Settlement: £148,000 (staff injury compensation, property damage — racking and stock damage, business interruption for the day's warehouse operations). Defence costs: £22,000. Total claim: £170,000.
Post-claim renewal: PL premium increased 40%. Insurer required: formal testing and demonstration protocol documentation; GPS/positioning environment pre-assessment for all demonstration venues; safety exclusion zone established around prototype during operation; written demonstration agreement with client facility signed before any demonstration. The company implemented these.
The lesson: the prototype/product distinction is underwriters' language, not legal language. A prototype causing third-party injury during a demonstration creates PL and potentially PL exposure regardless of commercial stage. Testing and demonstration scenarios need specific risk assessment — not the same protocol as internal lab testing. Public Liability must explicitly extend to field testing and third-party site demonstration activity.
Claim — IP Infringement Dispute, £220,000 Defence Cost Recovery
A deep tech company had developed a novel battery chemistry for high-density energy storage applications. The technology had been developed from university research, licensed through a spinout agreement with the technology transfer office. Eighteen months after commercial launch, the company received a cease-and-desist letter from a German energy technology conglomerate claiming that two core aspects of the battery architecture infringed patents held in the UK under the Patents Act 1977. The conglomerate's UK patent portfolio had not been identified in the freedom-to-operate search conducted at the spinout stage — partly because the FTO search had been desktop-level rather than comprehensive, and partly because one of the relevant patents had been filed in a continuation series and the continuation had published after the FTO date.
The company had taken out IP Liability insurance at the insistence of its lead investor. The IP insurer engaged specialist patent solicitors immediately on notification. Legal analysis concluded that one of the two alleged infringements was defensible; the other had merit and required a licensing solution. The insurer managed the defence and negotiated a perpetual licence on the second claim.
Defence costs: £220,000 (specialist patent solicitors, technical expert witnesses, UK IPO submissions, licensing negotiation). Licence value: £85,000 one-off payment. Total insured outflow: £305,000 — fully recovered by the IP insurer. Without IP Liability insurance, these costs would have fallen entirely on the company and would almost certainly have been fatal to its operations.
The lesson: the freedom-to-operate search is a risk assessment, not an insurance substitute. An FTO can miss continuation patents, divisional applications, and patents that publish after the search date. IP Liability insurance is the practical mitigation for the residual risk that the FTO doesn't eliminate. Average UK IP claim costs exceed £150,000 in legal fees alone before any settlement — a figure that absorbs most of the operating cash of early-stage tech companies. Lead investors are right to require it.
Claims Management Steps for Experimental Technology Companies
How to respond to an insurance claim, regulatory engagement, or IP dispute — the steps below reflect the multi-policy, multi-regulator, multi-stakeholder environment that experimental technology companies operate in:
- Identify which policy or policies are engaged immediately. Experimental tech claims often engage multiple policies simultaneously — Tech PI (advice/design failure), Products Liability (product failure), Cyber (data breach), D&O (director conduct), IP Liability (infringement claim), Legal Expenses (regulatory investigation). Single notification to your broker who coordinates across all lines.
- Notify all potentially relevant insurers at "may give rise to a claim" threshold. Don't wait for formal claim documentation. The notification threshold under most PI and PL policies is "awareness of circumstances that may give rise to a claim" — not receipt of a letter of claim. Late notification is a common reason insurers reserve their position.
- Preserve all technical documentation immediately. Source code version control at the relevant date; model training datasets and documentation; design specifications; test protocols and results; client communications; specification agreements; acceptance testing records. Technical documentation is the primary defence evidence across all experimental tech claim types.
- Do not make admissions or representations about the technology's failure mode. Technical honesty internally is essential; external representations about what failed and why should be made through legal representation. Early admissions about design choices or known limitations can be used against the company in litigation.
- Engage specialist legal representation for tech IP and regulatory disputes. Generic solicitors are not adequate for patent infringement defence, MHRA regulatory investigations, ICO enforcement actions, or FCA enquiries. Your Legal Expenses insurer should provide access to specialist panel solicitors — insist on this rather than accepting general practice referrals.
- Manage investor communication carefully and through counsel. Where a claim implicates the company's technology direction or financial position, investor communications should be managed with D&O insurers and legal counsel aware of what is being said. Representations made to investors in a crisis can create secondary D&O exposure.
- Conduct root cause analysis with technical expert involvement. What failed, why it failed, and what the technical record shows were the known risks — these three questions determine the claim outcome. Internal root cause analysis should be privileged where possible; external technical expert reports should be commissioned through legal representation.
- Update technology documentation and risk management to address the identified gap. Insurers reviewing renewal after a claim will ask what has changed. The post-claim documentation improvement — DPIA completed, model governance implemented, FTO updated, testing protocols revised — is both insurance and commercial evidence that the company has addressed the root cause.
Glossary of experimental technology insurance terms
- PRAM Act (Product Regulation and Metrology Act 2025)
- UK framework legislation receiving Royal Assent on 21 July 2025 that for the first time explicitly brings "intangible components" — including software, algorithms, and AI systems — within the scope of UK product safety regulation. Creates powers for the Secretary of State to introduce specific obligations via secondary legislation; experimental tech companies should prepare compliance documentation now.
- Technology Professional Indemnity (Tech PI / Tech E&O)
- Specialist Professional Indemnity insurance designed for technology companies covering claims arising from errors, omissions, and failures in technology products and services. Distinct from standard PI in that it explicitly covers software failure, algorithmic error, systems integration failure, and privacy liability. Also called Technology Errors and Omissions (Tech E&O) in US/international markets.
- AI Exclusion
- Policy wording added or updated by some mainstream UK insurers in 2024–2025 to exclude claims arising from AI-generated outputs, autonomous decision-making, or AI system failure. Companies relying on policies issued before 2025 renewal should check whether new AI exclusion language was added at renewal.
- Freedom to Operate (FTO) Search
- Legal analysis conducted before commercialisation of a new technology to determine whether the technology can be manufactured, used, or sold without infringing existing third-party patents. A prerequisite for effective IP risk management — FTO reduces but does not eliminate patent infringement risk, particularly for continuation patents filed after the search date.
- IP Liability Insurance
- Insurance covering defence costs and damages where a company is accused of infringing third-party intellectual property rights including patents, copyrights, trademarks, and trade secrets. Distinct from IP prosecution insurance (which covers costs of enforcing your own IP rights). Both are available from specialist insurers; neither is included in standard commercial or Tech PI policies without specific endorsement.
- Directors and Officers (D&O) Insurance
- Insurance covering the personal legal liability of company directors and officers for wrongful acts in the management of the company. Particularly important for funded technology companies where VC investors hold equity and may bring claims for breach of fiduciary duty, misleading fundraising representations, or negligent business decisions.
- Products Liability
- Insurance covering claims arising from injury or property damage caused by a product the company has manufactured, supplied, or sold. In the UK, strict liability applies under the Consumer Protection Act 1987 — a claimant need not prove negligence, only that the product was defective. For experimental technology, the definition of "defective" for novel products is legally uncertain and evolving under the PRAM Act framework.
- Run-Off Cover
- Professional Indemnity cover that continues to respond to claims notified after the policy period has ended, provided the work was performed during the original policy period. Essential for technology companies — PI policies are "claims made" and a company that ceases trading or is acquired without run-off cover loses protection for all past work. Typical run-off periods: 3–6 years minimum for tech PI.
- Consumer Protection Act 1987 (CPA 1987)
- The primary UK product liability statute imposing strict liability on producers for defective products. Currently under Law Commission review (launched July 2025) to address its inadequacies in covering software, AI systems, and digital products. Until reform is enacted, CPA 1987 applies in parallel with the PRAM Act framework.
- DPIA (Data Protection Impact Assessment)
- Formal risk assessment required under UK GDPR where a technology processes personal data in a way likely to result in high risk to individuals — including automated decision-making, large-scale processing of sensitive data, and systematic monitoring. Completion of a DPIA is both a legal obligation and an underwriting requirement for cyber policies covering AI data processing.
- Environmental Impairment Liability (EIL)
- Specialist insurance covering liability for pollution, contamination, and environmental damage. Standard Public Liability policies carry broad pollution exclusions. EIL is essential for experimental tech companies working with novel materials, chemicals, biological agents, or advanced manufacturing processes that could create environmental release incidents.
- Model Governance
- The documented framework governing how an AI or machine learning model is developed, tested, deployed, monitored, and updated. Model governance documentation — including training data provenance, bias testing, performance monitoring, and version control — is increasingly required by tech insurers as a condition of AI liability cover and as evidence in AI-related PI claims.
- Patent Assertion Entity (PAE)
- A company that acquires patents primarily to monetise them through licensing or litigation rather than to practice the technology. PAEs disproportionately target commercialising startups with revenue that makes licensing demands commercially meaningful. IP Liability insurance is the primary mitigation for PAE exposure — and defence costs against PAE claims routinely exceed £200,000.
- MHRA (Medicines and Healthcare products Regulatory Agency)
- UK regulator for medical devices and health technologies. MedTech innovators face MHRA approval obligations, vigilance reporting requirements, and post-market surveillance duties. MHRA regulatory investigation and enforcement action is an insurable risk under Legal Expenses Insurance with the appropriate regulatory investigation scope.
Frequently asked questions
The core programme for experimental technology companies in 2026 includes: Technology Professional Indemnity (Tech PI / Tech E&O) with AI and novel technology scope explicitly confirmed; Products Liability with untested and novel technology cover (not a standard commercial products endorsement); Cyber Insurance with AI failure and third-party technology liability scope; IP Liability Insurance covering patent, copyright, and trade secret infringement defence; Directors and Officers (D&O) for any funded company; Employers' Liability (legally required with staff); and Legal Expenses with regulatory investigation scope covering MHRA, ICO, FCA, and sector-specific regulators as applicable. The precise mix depends heavily on technology type — AI, robotics, MedTech, hardware, and deep tech each have distinct priority exposures. Standard commercial policies are almost never adequate; specialist tech placement is essential.
The PRAM Act (Product Regulation and Metrology Act 2025), which received Royal Assent on 21 July 2025, is the first UK legislation to explicitly bring software, algorithms, and AI systems within the scope of product safety regulation as "intangible components." It creates powers for the Secretary of State to introduce specific obligations via secondary legislation — meaning the compliance requirements for experimental tech companies will materialise progressively through 2026–2028. Companies should prepare now by developing PRAM Act-ready technical documentation: safety testing records, product scope documents, risk assessments, and compliance evidence. This documentation also serves as underwriting evidence for products liability cover and reduces insurer risk perception — meaning better premium terms and fewer coverage disputes at claim stage.
Several mainstream UK insurers updated their policy wordings in 2024–2025 to add explicit exclusions for AI-generated outputs, autonomous decision-making liability, and AI system failure. Companies that renewed policies without their broker specifically checking for this new language may now hold Tech PI or cyber policies that exclude their core technology category. This is particularly acute for companies that describe their technology as "software" at proposal — if the software includes autonomous AI decision-making, the AI exclusion may apply to the very claims the company is most likely to face. The solution is a policy wording review at the next renewal and, where AI exclusions are found, explicit endorsement or specialist placement that removes them. A specialist tech broker should confirm in writing at every renewal that no new AI exclusion has been added.
Yes — and most VC term sheets at Series A and beyond will require it. D&O insurance covers the personal legal liability of directors and officers for wrongful acts in managing the company. Once investors hold equity, directors owe fiduciary duties to those investors — technology direction decisions, fundraising representations, burn rate decisions, and regulatory compliance failures can all generate D&O claims when a company fails to meet investor expectations or a technology pivot destroys invested value. Limits typically £1m–£5m at Series A; £5m–£10m+ at Series B and beyond. D&O should also include run-off cover provisions — M&A and IPO events are common triggers for D&O claims surfacing from decisions made pre-transaction. Arrange D&O before investor due diligence begins, not as an afterthought once the term sheet is signed.
Indicative 2026 annual premiums: software/SaaS without AI components £2,500–£6,000; AI/ML startups £6,000–£15,000; hardware prototype developers £5,000–£12,000; robotics/autonomous systems companies £12,000–£30,000; MedTech innovators £15,000–£45,000+; deep tech/university spinouts £10,000–£35,000; scaled AI/tech platforms at Series B+ £25,000–£80,000+. The most significant cost driver is technology type — autonomous systems, MedTech, and AI decision-making tools carry substantially higher premiums than standard software. Within any technology category, documentation maturity is the biggest within-band premium lever: PRAM Act-ready technical documentation, completed DPIAs, model governance records, and FTO searches can collectively reduce premiums 15–25% against peers without this documentation.
For most experimental technology companies, yes — by a significant margin. IP insurance submissions rose 40% in H1 2025 driven by AI and software firms. The average UK IP claim now exceeds £150,000 in legal costs alone. Patent assertion entities specifically target commercialising startups with revenue that makes licensing demands commercially viable. A freedom-to-operate search reduces but doesn't eliminate infringement risk — continuation patents, divisional applications, and patents filed after the FTO date are all genuine exposure sources. Annual IP Liability insurance typically costs £2,000–£8,000 for early-stage tech companies — substantially less than a single claim defence engagement. Lead investors are right to require it. See the IP claim case study above for a practical illustration of what the cover recovers.
Not always — and confirming this is one of the most important checks an AI company should make in 2026. Standard Tech PI covers professional liability arising from technology services — but AI exclusions added to some policies in 2025 mean that claims arising from AI-generated outputs, autonomous decision-making errors, or AI model failure may be carved out. The check is simple: get written confirmation from your broker that your Tech PI policy explicitly covers: AI and machine learning outputs; automated decision-making liability; claims arising from AI model error or bias. If that confirmation can't be provided in writing, the policy needs to be re-examined. Specialist tech insurers underwrite AI-specific Tech PI without these exclusions; mainstream commercial markets often don't.
The transition from prototype to commercial deployment is one of the most critical insurance review triggers — and one that many experimental tech companies miss because they are focused on the commercial milestone rather than the insurance implications. When technology moves from development/pilot to commercial deployment, several things change simultaneously: Products Liability exposure becomes acute where the technology interacts with third-party users or their property; Tech PI exposure increases as client contracts generate professional liability; cyber exposure increases as client data is processed at scale; and D&O exposure increases if funding has been raised partly on the commercial deployment milestone. Mid-term notification to your insurer is required when deployment stage changes materially — don't wait for renewal. Brokers should be notified when any of these milestones occur: first client contract signed; first revenue generated; first deployment on a client's systems.
Yes — university indemnities do not extend to spinout entities. The spinout is a separate legal entity the moment it is incorporated, and from that point it bears its own liability. University insurance covers the university's activities; spinout activities — commercialising the technology, entering client contracts, employing staff, deploying products — are not covered by the university's programme. The specific spinout insurance challenges are: IP ownership disputes where the background IP boundary with the university is unclear; Tech PI where the founding technology overlaps with ongoing university research; D&O where the university technology transfer office holds shares or board observer rights; and prototype cover where equipment moves from university laboratory to spinout control. All of these require specific placement — not assumption of coverage under any university-adjacent insurance arrangement.
Look for brokers who can demonstrate specific experience with experimental technology, AI liability, and deep-tech startup risk — evidenced by: the ability to articulate the difference between standard Tech PI and AI-specific Tech PI without prompting; access to Lloyd's market and specialist MGA schemes for product liability and IP coverage; familiarity with the PRAM Act, Law Commission product liability review, and AI governance requirements; willingness to provide written confirmation of coverage scope for specific technology types. Avoid brokers offering generic "tech company packages" without drilling into your technology category; brokers who cannot name the specific underwriter or MGA placing your product liability risk; and brokers who treat AI, robotics, MedTech, and standard SaaS as interchangeable risk categories. Miller & Partner specialise in this sector — visit our AI and tech insurance hub and tech contractors insurance page for our specialist product coverage.
Run-off cover is Professional Indemnity insurance that continues to respond to claims notified after the policy period has ended, provided the work was performed during the original policy period. It matters critically for experimental tech companies for two reasons. First, Tech PI policies are issued on a "claims made" basis — meaning the policy in force when a claim is notified must respond, not the policy in force when the work was done. If a company ceases trading, is acquired, or simply allows a PI policy to lapse without run-off cover, all past professional work becomes uninsured. Second, technology claims surface with a significant lag — an AI system deployed in 2024 may not generate a PI claim until the harm from its error becomes apparent in 2026 or 2027. Run-off cover for at least 3–6 years is the appropriate protection for most tech PI exposure. See our professional indemnity insurance guide for run-off cover principles.
Cyber insurance and Tech PI are related but distinct covers that address different aspects of technology risk. Cyber insurance covers losses arising from data breaches, ransomware, network intrusion, and digital attacks — both the company's own first-party costs (forensics, business interruption, notification costs) and third-party liability to affected individuals and organisations. Tech PI covers professional liability arising from errors, omissions, and failures in technology services and products — what went wrong with what you built or advised, rather than what went wrong with the security of your systems. For experimental tech companies, both are essential and they need to be checked for AI-specific scope: cyber for AI failure causing data compromise or third-party system damage; Tech PI for AI error causing client financial loss. Some specialist tech insurers bundle cyber and Tech E&O in a combined technology policy — check the AI scope in both elements. See our cyber insurance guide for the detailed cover architecture.
Instagram
LinkedIn